ONCOLYTICS REPORTS REOLYSIN TRIAL RESULTS

A A

Oncolytics Biotech has reported interim results from its Phase I combination Reolysin/radiation clinical trial, which showed that the combination of intra-tumoral Reolysin and radiation was well-tolerated. Also, the company stated that both local clinical responses and early indications of systemic effects were observed.

The primary objective of the open-label study is to determine the maximum tolerated dose and dose limiting toxicities, if any. The secondary objective is to examine any evidence of anti-tumor activity.